MKI67 and metastatic neoplasm: There is a growing body of evidence describing tumor biomarker conversion, i.e. upregulation or downregulation of hormone receptors, HER2/ERBB2 and Ki-67/MKI67 when comparing metastatic tumors (MT) with primary tumors (PT) [7–19].